Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Mitchell, R, Trück, J, Pollard, A
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	2013

Ижил төстэй зүйлс

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
-н: Trück, J, зэрэг
Хэвлэсэн: (2016)

Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine
-н: Trück, J, зэрэг
Хэвлэсэн: (2018)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
-н: V. K. Tatochenko, зэрэг
Хэвлэсэн: (2012-03-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
-н: James T. Peterson, зэрэг
Хэвлэсэн: (2019-03-01)

13-valent pneumococcal conjugate vaccine in Africa
-н: Robert Cohen, зэрэг
Хэвлэсэн: (2017-03-01)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
-н: Susanna Esposito, зэрэг
Хэвлэсэн: (2015-01-01)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
-н: Irina Kislaya, зэрэг
Хэвлэсэн: (2019-01-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
-н: Kristiana Alexandrova Nikolova, зэрэг
Хэвлэсэн: (2021-10-01)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
-н: L A Shpagina, зэрэг
Хэвлэсэн: (2018-11-01)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
-н: Johnna Perdrizet, зэрэг
Хэвлэсэн: (2021-04-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
-н: Beate Schmoele-Thoma, зэрэг
Хэвлэсэн: (2019-03-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
-н: S. M. Kharit, зэрэг
Хэвлэсэн: (2016-12-01)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
-н: Corinne Levy, зэрэг
Хэвлэсэн: (2021-08-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
-н: Filippo Ansaldi, зэрэг
Хэвлэсэн: (2020-01-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
-н: Paul Turner, зэрэг
Хэвлэсэн: (2015-11-01)

Pneumococcal serotypes causing pneumonia in the 13 valent pneumococcal conjugate vaccine era in Australian children
-н: R. Strachan, зэрэг
Хэвлэсэн: (2020-12-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
-н: Hye-Young Kim, зэрэг
Хэвлэсэн: (2021-03-01)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
-н: Miguel Gouveia, зэрэг
Хэвлэсэн: (2019-04-01)

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.
-н: Jo Southern, зэрэг
Хэвлэсэн: (2018-01-01)

Experience with 13-valent conjugated pneumococcal vaccine in HIV-infected patients
-н: A. V. Zhestkov, зэрэг
Хэвлэсэн: (2020-12-01)

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
-н: Rodgers, G, зэрэг
Хэвлэсэн: (2013)

Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil
-н: Indianara Maria Grando, зэрэг
Хэвлэсэн: (2015-02-01)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
-н: Albert Jan van Hoek, зэрэг
Хэвлэсэн: (2016-01-01)

Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules
-н: Hong-Yi Lee, зэрэг
Хэвлэсэн: (2018-04-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
-н: Sweta M Patel, зэрэг
Хэвлэсэн: (2022-01-01)

Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
-н: Kristiana Alexandrova Nikolova, зэрэг
Хэвлэсэн: (2024-02-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
-н: Sweta M. Patel, зэрэг
Хэвлэсэн: (2022-01-01)

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2–59 Months of Age, Spain
-н: Sergi Hernández, зэрэг
Хэвлэсэн: (2020-06-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
-н: Sabine Haggenburg, зэрэг
Хэвлэсэн: (2023-07-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
-н: Matthew Wasserman, зэрэг
Хэвлэсэн: (2019-03-01)

Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy.
-н: Romina Camilli, зэрэг
Хэвлэсэн: (2013-01-01)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
-н: Matt Wasserman, зэрэг
Хэвлэсэн: (2021-06-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
-н: Hannah M. Garcia Garrido, зэрэг
Хэвлэсэн: (2022-05-01)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children
-н: Ayieko, P, зэрэг
Хэвлэсэн: (2013)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
-н: Philip Ayieko, зэрэг
Хэвлэсэн: (2013-01-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
-н: Earnshaw Stephanie R, зэрэг
Хэвлэсэн: (2012-04-01)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
-н: Min-Joo Choi, зэрэг
Хэвлэсэн: (2018-08-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
-н: Thundon Ngamprasertchai, зэрэг
Хэвлэсэн: (2023-06-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
-н: N. L. Chernaya, зэрэг
Хэвлэсэн: (2012-02-01)

Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
-н: B. T. Batozhargalova, зэрэг
Хэвлэсэн: (2024-03-01)